⌘K
t
| TIDM | AMS |
| Share Price | GBX 279.500.18% |
| Market Cap | £613.79m |
Advanced Medical Solutions Group plc announced that Director and PDMR Chris Meredith exercised 395,355 LTIP options, 34,608 DAB options, and 23,415 DSB shares, received 543 DAB dividend shares and an award of 56,785 DSB shares, and sold 246,384 shares at 271.5p each on May 10, 2022. Fellow Director and PDMR Eddie Johnson was awarded 17,225 DSB shares, and the Trust purchased 8,945 shares on his behalf between May 10-12, 2022, at an average of 270.5p. Following these transactions, Chris Meredith's holding is 1,760,162 Ordinary Shares (0.82%) and Eddie Johnson's is 84,309 Ordinary Shares (0.04%).
| Date | 13 May 2022 |
| Time | 18:08:54 |
| Category | Director/PDMR dealings |
| ID | 5200L |
|
|
13 May 2022 |
("AMS", the "Company" or the "Group")
Winsford, UK: Advanced Medical Solutions Group plc (AIM: AMS), the world-leading specialist in tissue-healing technologies, announces the following PDMR share transactions.
The Company was notified on 10 May 2022 that following his decision to participate in the Deferred Share Bonus (DSB), Chris Meredith, who is a Director and PDMR, undertook the following transactions:
· The exercise of 395,355 options from the Long-Term Incentive Plan (LTIP).
· The exercise of 34,608 options from the existing Deferred Annual Bonus Plan (DAB).
· Elected to receive an additional 543 dividend shares which were earned during the holding period under the terms of the DAB.
· The exercise of 23,415 Ordinary Shares of 5p from the existing DSB and the award of 56,785 shares under the DSB.
· The sale of 246,384 Ordinary Shares of 5p each on 10 May 2022 at a share price of 271.5p per Ordinary Share by way of an off-market sale. The proceeds from the sale of the shares was used to purchase shares in the DSB and cover the tax payable on the above exercises.
The Trust which manages the Deferred Share Bonus Plan ("DSB") on behalf of the employees of AMS purchased ordinary shares of 5 pence each ("Ordinary Shares") between 10 and 12 May 2022, at an average price of 270.5p on behalf of Chris Meredith as part of the DSB and, under the terms of the DSB, these shares will be held in trust on his behalf.
As a result of these transactions Chris Meredith's beneficial interest in the Company increased and his overall holding is as follows:
|
PDMR |
No. of DSBs after exercise |
No. of DABs after exercise |
No. of LTIPs after exercise |
Resultant holding of Ordinary Shares |
% of issued share capital |
|
Chris Meredith |
117,709 |
6,219 |
877,145 |
1,760,162 |
0.82% |
The Company was also notified on 12 May 2022 that following the decision by Eddie Johnson, who is a Director and PDMR, to participate in the DSB the Trust which manages the Deferred Share Bonus Plan ("DSB") on behalf of the employees of AMS purchased ordinary shares of 5 pence each ("Ordinary Shares") between 10 and 12 May 2022, at an average price of 270.5p on behalf of Eddie Johnson as part of the DSB and, under the terms of the DSB, these shares will be held in trust on his behalf. Eddie Johnson was awarded of 17,225 shares under the DSB.
As a result of these transactions Eddie Johnson's beneficial interest in the Company increased and his overall holding is as follows:
|
PDMR |
No. of DSBs after exercise |
No. of DABs held |
No. of LTIPs held |
Resultant holding of Ordinary Shares |
% of issued share capital |
|
Eddie Johnson |
110,140 |
12,737 |
348,258 |
84,309 |
0.04% |
The notification below, made in accordance with the requirements of the EU Market Abuse Regulation, provides further detail.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. |
Details of the person discharging managerial responsibilities/person closely associated |
||||
|
a) |
Name: Chris Meredith |
||||
2. |
Reason for the notification |
||||
|
a) |
Position/status: Director/PDMR |
||||
|
b) |
Initial notification/Amendment: Initial Notification |
||||
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
||||
|
a) |
Name: Advanced Medical Solutions Group plc |
||||
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
||||
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
||||
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
||||
|
b) |
Nature of the transactions: · Exercise of 23,415 shares from the Deferred Share Bonus Plan · Exercise of 34,608 shares from the Deferred Annual Bonus Plan · Award of 543 Dividend Shares from the Deferred Annual Bonus Plan · Exercise of 395,355 shares from the Long-Term Incentive Plan · Sale of 246,384 shares · Purchase of 28,725 shares through the Deferred Share Bonus Plan · Award of 56,785 shares in the Deferred Share Bonus Plan |
||||
|
c) |
Price(s) and volume(s): Sale of shares:
|
||||
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: 246,384 Aggregated price: £2.715 |
||||
|
e) |
Date of the transaction: 10/05/2022 |
||||
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
1. |
Details of the person discharging managerial responsibilities/person closely associated |
|
a) |
Name: Eddie Johnson |
2. |
Reason for the notification |
|
a) |
Position/status: Director/PDMR |
|
b) |
Initial notification/Amendment: Initial Notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name: Advanced Medical Solutions Group plc |
|
b) |
LEI: 213800HJP6OWOSZI1L74 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the financial instrument, type of instrument: Ordinary Shares of 5p Identification code: GB0004536594 |
|
b) |
Nature of the transaction: · Purchase of 8,945 shares through the Deferred Share Bonus Plan · Award of 17,225 shares in the Deferred Share Bonus Plan |
|
c) |
Price(s) and volume(s): Sale of shares: Nil |
|
d) |
Aggregated information: (Relates to those shares sold only) Aggregated volume: Aggregated price: |
|
e) |
Date of the transaction: 10/05/2022 |
|
f) |
Place of the transaction: London Stock Exchange, AIM Market (XLON) |
-End -
For further information, please visit www.admedsol.com or contact:
|
Advanced Medical Solutions Group plc |
Tel: +44 (0) 1606 545508 |
|
Chris Meredith, Chief Executive Officer Eddie Johnson, Chief Financial Officer |
|
|
|
|
|
Consilium Strategic Communications |
Tel: +44 (0) 20 3709 5700 |
|
Mary-Jane Elliott / Matthew Neal / Matthew Cole |
|
|
|
|
|
Investec Bank PLC (NOMAD & Broker) |
Tel: +44 (0) 20 7597 5970 |
|
Daniel Adams / Gary Clarence |
|
|
|
|
|
HSBC Bank PLC (Broker) |
Tel: 44 (0) 20 7991 8888 |
|
Sam McLennan / Joe Weaving / Stephanie Cornish |
|
About Advanced Medical Solutions Group plc - see www.admedsol.com
AMS is a world-leading independent developer and manufacturer of innovative tissue-healing technology, focused on quality outcomes for patients and value for payers. AMS has a wide range of surgical products including tissue adhesives, sutures, haemostats, internal fixation devices and internal sealants, which it markets under its brands LiquiBand®, RESORBA®, LiquiBandFix8® and Seal-G®. AMS also supplies wound care dressings such as silver alginates, alginates and foams through its ActivHeal® brand as well as under white label. Since 2019, the Group has made three acquisitions: Sealantis, an Israeli medical device company with a patent-protected sealant technology platform; Biomatlante, an established French developer and manufacturer of innovative surgical biomaterial technologies and Raleigh, a UK leading coater and converter of materials predominately for woundcare and bio-diagnostics products.
AMS's products, manufactured in the UK, Germany, France, the Netherlands, the Czech Republic and Israel, are sold globally via a network of multinational or regional partners and distributors, as well as via AMS's own direct sales forces in the UK, Germany, the Czech Republic and Russia. The Group has R&D innovation hubs in the UK, Germany, France and Israel. Established in 1991, the Group has more than 700 employees. For more information, please see www.admedsol.com.